^
    Back
    Association details:
    Biomarker:KDM4B overexpression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Pathol
    Title:

    Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor targeted therapy in advanced prostate cancer

    Published date:
    07/03/2020
    Excerpt:
    Here we found that KDM4B is overexpressed in enzalutamide-resistant prostate cancer cells.
    DOI:
    10.1002/path.5495